article · Toxicology and Applied Pharmacology

Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome

Kehinde S. Olaniyi
Mohd Zahoor ul haq Shah
Stephanie E. Areloegbe
Isaac O. Ajadi
Chukwubueze L. Atuma
Isaiah Woru Sabinari
Adedamola Adediran Fafure
Emmanuel Damilare Areola
Richard Dele Agbana
Lawrence A. Olatunji

202310 citationsLadoke Akintola University of Technology

In plain language

No abstract is available for this record, so no summary has been generated.

Research topics

Ovarian function and disorders
Hormonal Regulation and Hypertension
Antioxidant Activity and Oxidative Stress

Sustainable Development Goals

Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1016/j.taap.2023.116604

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.